Oshi Health Raises $30M to Grow Gastrointestinal Care Company

Oshi Health, a digital gastrointestinal health company, has announced that it has secured $30 million in Series B funding. Koch Disruptive Technologies (KDT) led the round with participation from existing investors Flare Capital Partners, Bessemer Venture Partners, CVS Health Ventures, First Chrissy Ventures and Takeda Digital Ventures. What they do Oshii provides virtual access to a team of providers including a gastroenterologist, behavioral health clinician, dietician and health coach for patients with gastrointestinal problems. The company provides support for digestive disorders such as Crohn’s disease, irritable bowel syndrome (IBS) and ulcerative colitis. Patients can use the company’s symptom tracking tool and instant messaging with their providers. The New York-based company will use the funding to add to its clinical team in the US and expand its reach with employers, provider groups, health plans and channel partners. “We’ve seen the impact of Oshie Health’s unique care model, and we want to be a part of helping health plans and employers realize the tremendous potential of virtual multidisciplinary digestive care,” said David Mauney, managing director of Koch Disruptive Technologies. press release. “We are excited to help Oshie’s best-in-class virtual clinic and clear market leadership deliver proven results.” MARKET SNAPSHOT Last week, Aetna, owned by CVS Health, announced a value-based care partnership with Oshie, which will offer business members in Florida, Maine, Massachusetts, Ohio, Pennsylvania and Texas with Aetna Oshie as a network provider. In the year In 2022, virtual care company Firefly Health announced a partnership with Oshie to offer digital digestive care to its members. Solera Health, a digital platform that provides a marketplace for benefits and chronic disease management programs, has announced that it will also offer gastrointestinal-focused digital health products from Oshi. In the year In 2021, Oshie Health received $23 million in Serie A funding. Dr. Toufia Haddad, Becky Kotchade, and Rebecca Heft will provide more details in the HIMSS23 session, “Approaches to Decentralized Clinical Trials.” It is scheduled for Wednesday, April 19, from 10 am – 11 am CT in the South Building, Level 5, Room S501.

Leave a Reply

Your email address will not be published. Required fields are marked *